Purpose: Post-thrombotic syndrome (PTS) remains a challenging and debilitating consequence of deep vein thrombosis (DVT). It can severely impair quality of life and lead to serious complications such as chronic ulceration. Evidence from randomized controlled trials suggests that mechanical thrombectomy (MT) may reduce the incidence of PTS compared to anticoagulation therapy alone in cases of proximal lower limb DVT. The Inari ClotTriever device represents a promising innovation in MT, demonstrating favourable results in terms of symptom relief, safety, and overall efficacy. This study presents a single-centre review of the use of the ClotTriever. We examine clinical outcomes, incidence of post-treatment PTS, and propose practical recommendations for patient selection and device utilization. Methodology: Patients presenting with proximal DVT who underwent MT using the ClotTriever device were included in this review. Exclusion criteria encompassed patients with below-knee DVT or symptom duration exceeding 4 weeks. Post-treatment outcomes were evaluated using the Villalta scoring system to assess the presence and severity of PTS. Results: 6 cases, performed between March and June 2025 were included in this series. All patients presented with proximal femoral, iliofemoral, or iliocaval DVTs. Pre-operative Villalta scores ranged from 7 to 11, primarily reflecting symptoms of pain and oedema. At six weeks post-operatively, 4 patients reported a significant reduction in pain, swelling and a 3-4 point reduction in Villalta score. Conclusion: The ClotTriever emerges as an effective and user-friendly MT solution for the management of proximal lower limb DVT. Patients treated with this device experienced rapid and marked symptomatic improvement. Notably, no cases of severe post-thrombotic syndrome were observed during follow-up. These findings underscore the ClotTriever's potential as a transformative tool in the prevention of long-term DVT complications.